Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.87 |
| ▸ | PLK3 | Q9H4B4 | 14/20 | 0.87 |
| ▸ | PLK2 | Q9NYY3 | 13/20 | 0.87 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.85 |
| ▸ | CLK2 | P49760 | 3/20 | 0.85 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.85 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.85 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.85 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.85 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.85 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.85 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.85 |
| ▸ | PRKCG | P05129 | 2/20 | 0.85 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.85 |
| ▸ | NEK4 | P51957 | 2/20 | 0.85 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.85 |
| ▸ | BRD4 | O60885 | 6/20 | 0.81 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.81 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971992 | 1.00 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL29922386 | 1.00 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL29453442 | 1.00 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL15257514 | 0.99 | PLK1 (0.87) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL30356851 | 0.94 | PLK1 (0.81) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL31098099 | 0.94 | PLK1 (0.81) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL12825254 | 0.94 | PLK1 (0.84) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL12323284 | 0.94 | PLK1 (0.85) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL14215917 | 0.93 | PLK1 (0.80) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL30325075 | 0.93 | PLK1 (0.86) | PLK1PLK3PLK2PRKD3CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316054-A1 | NOVEL PLK1 PROTEIN DEGRADATION-INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024117789-A1 | PLK1 DEGRADATION INDUCING COMPOUNDS WITH INCREASED RIGIDITY | UPPTHERA, INC. (KR) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024054952-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054954-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054954-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2008050078-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007135374-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | PLK4, TK1, POLK | PLK1 6/4885PLK3 18/4885PLK2 4/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | PLK1 3075/4885PLK3 4761/4885PLK2 4750/4885 |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | PLK1 1349/4885PLK3 2605/4885PLK2 2076/4885 |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | QDPR, DHPS, DHODH | PLK1 4090/4885PLK3 3119/4885PLK2 3856/4885 |
| US-20240316054-A1 | NOVEL PLK1 PROTEIN DEGRADATION-INDUCING COMPOUND | PLK1, BRD4, BUB1B | PLK1 1/4885PLK3 97/4885PLK2 43/4885 |
| US-20080293944-A1 | Piperazinyl Compounds | QDPR, DHPS, DPYD | PLK1 3628/4885PLK3 1355/4885PLK2 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.